Title : Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.

Pub. Date : 2012 Nov 8

PMID : 22955915






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 TP53 mutation is an independent marker of poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL) treated with cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (CHOP) therapy. Vincristine tumor protein p53 Homo sapiens